EICHOR
● Recruiting
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
Condition: Cutaneous Melanoma · Cutaneous Melanoma, Stage III · Cutaneous Melanoma by AJCC V7 Stage · Sponsor: University of California, San Francisco
About this study
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the impact of ICIs on patients' symptom experiences. An in-depth characterization of inter-individual differences in patients' symptom experiences will fill this knowledge gap and assist with the early detection of ICI toxicity; guide symptom management; inform treatment decision making; and refine ICI-symptom instrument development. Furthermore, given the limited knowledge in this area, the identification of demographic, clinical, environmental, and molecular risk factors associated with a worse symptom experience is warranted. This is a longitudinal, prospective study evaluating the symptoms that immune checkpoint inhibitors may cause in patients with cutaneous melanoma.
This description comes directly from the study's public registry record.
Talk to the study team
Erin Hubbard, MPH · (415) 502-7774 · Erin.Hubbard@ucsf.edu
Carolyn Harris, PhD, RN · Carolyn.Harris@ucsf.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.